Gabapentin to Reduce Postoperative Nausea and Vomiting

Gabapentin Premedication to Reduce Postoperative Nausea and Vomiting in Surgical Patient Receiving Spinal Morphine

Status

Completed

Phases

Phase 4

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT02944981

Enrollment

Registered

2016-10-26

Start date

2016-08-31

Completion date

2017-02-28

Last updated

2017-05-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Postoperative Nausea and Vomiting

Brief summary

The intrathecal administration of morphine is gaining popularity. It is easy to do and can reduce the pain after surgery up to 24 hours. However, it causes postoperative nausea and vomiting more than other methods providing postoperative analgesia. Patients suffering from these side effects have to spend a longer period of time recovering in the hospital with high cost of medical treatment.

Detailed description

Objective: to study the efficacy of oral administrating of gabapentin 600 mg before surgery to reduce the postoperative nausea and vomiting in patients receiving intrathecal morphine. Methods: Eighty patients undergoing orthopedic surgery and receiving intrathecal morphine will be randomized into 2 groups. The first group will receive oral gabapentin 600 mg and the second group will receive a placebo tablet. Both groups will receive a standard prophylactic medication for postoperative nausea and vomiting. The degrees of nausea and vomiting in both groups will be assessed over 24 hours postoperatively.

Interventions

DRUGGabapentin

Single oral dose

DRUGPlacebo

Single oral dose

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

PREVENTION

Masking

QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender

ALL

Age

18 Years to 65 Years

Healthy volunteers

Yes

Inclusion criteria

* Patients undergoing general or regional anesthesia receiving spinal morphine * ASA physical status I-III

Exclusion criteria

* Patients with allergy to morphine or gabapentin * Chronic use of narcotics * Psychotic * Bleeding disorder * Cardiovascular disorder * Liver or renal failure * Pregnancy or breast feeding * Neurologic disorder

Design outcomes

Primary

Measure	Time frame	Description
Postoperative nausea and vomiting (grade 1-3)	through study completion, an average of 24 hours	PONV grading: 0 = none; 1 = mild; 2 = moderate; 3 = severe

Countries

Thailand

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026